According to reports, Merck & Co. (MRK) is in discussions to acquire Revolution Medicines (RVMD), a biotechnology company focused on oncology. Sources familiar with the matter indicate that the transaction price being discussed is between $28 billion and $32 billion. If finalized, this would represent one of the largest deals in the pharmaceutical industry since Pfizer’s ($PFE.US) $43 billion acquisition of Seagen in late 2023.

Boosted by the news, Revolution Medicines saw its shares surge over 13% in Thursday’s U.S. overnight trading session as of press time.

Notably, reports on Wednesday suggested that AbbVie (ABBV) was in “advanced” talks to acquire Revolution Medicines, potentially valuing the pre-commercial company at over $20 billion. However, AbbVie subsequently responded that it was not in negotiations to acquire the firm.

Key Asset: Daraxonrasib (RMC-6236)

The cornerstone of Revolution Medicines’ portfolio is Daraxonrasib (RMC-6236), a cutting-edge, oral, direct-acting RAS(ON) multi-selective inhibitor. Designed to treat cancers driven by RAS gene mutations, the drug works by directly binding to the active state of the RAS protein. This blocks its interaction with downstream signaling proteins, thereby inhibiting the continuous activation of the RAS pathway and slowing the growth and proliferation of tumor cells.

Daraxonrasib targets common oncogenic RAS mutations, including G12X, G13X, and Q61X, which are critical drivers in major malignancies such as:

• Pancreatic Ductal Adenocarcinoma (PDAC)
• Non-Small Cell Lung Cancer (NSCLC)
• Colorectal Cancer (CRC)

Currently, Daraxonrasib is being evaluated in four global Phase 3 clinical trials, including three focused on PDAC and one on locally advanced or metastatic RAS-mutant NSCLC. Top-line results from key studies are expected to be released this summer.

Clinical Milestones and Market Potential

In December of last year, Revolution Medicines announced the enrollment of the first patient in the RASolute 304 trial. This global, open-label, Phase 3 study evaluates the safety and efficacy of Daraxonrasib in patients with resectable PDAC who have completed surgery and chemotherapy. The trial aims to enroll approximately 500 patients to determine if the drug can improve disease-free survival compared to observation alone.

Industry research suggests that, driven by Daraxonrasib, the pancreatic cancer drug market could expand tenfold to over $3 billion by 2035. Last October, the FDA selected Daraxonrasib for a new pilot program designed to accelerate the approval of promising drugs. Analysts expect the drug could receive market approval as early as 2026.

Strategic Significance for Merck

M&A activity in the pharmaceutical sector typically intensifies in January, coinciding with the annual J.P. Morgan Healthcare Conference in San Francisco, a known catalyst for deal-making. Analysts Javier Manso Polo and Sam Fazeli noted that while Revolution’s pipeline is highly attractive, any deal would carry execution risks and a significant valuation premium.

For Merck, the acquisition would be a strategic move to bolster its pipeline as its blockbuster immunotherapy, Keytruda, nears patent expiration at the end of this decade. Since 2021, Merck has nearly tripled its late-stage pipeline through internal development and major deals—such as the $11.5 billion acquisition of Acceleron. Acquiring Revolution Medicines would secure Merck the rights to the highly anticipated Daraxonrasib.